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days after stent ~ l ion .  The 1-year-event kee suneival rate was 98.4%. 
Condeeuon~" The data show tttat he maionty ot ~ t i c  patk~ts 
troth mstenosis Itave a favoreble ang~aphic a.,'KI clinical outo0me. Regres- 
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10:30 • Results of Intracomnary Recombinant Human 
Vascular Endothelial Growth Factor (rhVEGF) 
Administration Trial 
T.D. Henry, K. Rocha-Singh, J.M, Isner, D.J. Kemiakes, FJ. Giordano, 
M. Simons, D.W. Losordo, R.C. Hendel, R.O. Bonow, J.M. Rothman, 
E.R. Bodoas, E.R. McCluskey. Hennepin County Medical Center. 
Minneapofis, MN. Genentech, Inc., So. San Francisco, CA, USA 
Background: Few therapeutic option~" currently exiSt for 10tS with severe coro- 
nary artory disease who have areas of viable but underperfused myocardium 
and who are not optimat candidates for PTCA or CA~G. Atlima! models 
using rhVEGF have demonstrated angiogenesis leading to improvement in 
ischemic myocardium. This is the first human study designed to determine 
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~ m'~ a~r rmm o~ AMI. To c,tra~y ema~ee me role Of TNF. rekm~ m 
~ in~a~ s~,e. Sprague Oa~S rms ~mre mmmd wlrn a momck~ 
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181031 Morphine Mimk:= lachem~ Pmconclitionln0 in 
Human Myocami .m Oudng F tCA 
N.P. Xermpoufos, M Lesser, R. BoI1L ~ of Lou~v~We Meo'Ca/ 
Scho~. Loumwne, K~. USA 
Recent stua~s ~ that ~ receptors rne~te ~ preeon~d~n. 
mg in experimental mmals and that morphine m~mcs this car¢~o~ 
olfect. However, it is unknown wt~er  mOrphine p ~  human my. 
ocardhml. A~o~rd~ngly. 16i~lJents (pts) were ~z~B¢l  to recewe a 10.,rain 
~n(r"acococtary 0C) infusion of serme (controls [C|, n = 8) or moq~hine sulfate 
(MS) (n = 8, 15 p/kg). No hecqodyr~!c ringes w~'re noted dum~g Ihe IC 
infusion of MS. Ten mm after the completion of the IC ~ .  10is underwent 
,'~rcA (three 2~-nin ~ each separatod by 5 min). The ST-~ 
shirts horn baseline in the IC-ECG and in the sudace ECG (S-ECG) were 
measured at the end o! each inflation: X ~. SEM; "P ~ 0 05 vs ¢ontrcls. 
tC-ECG (ram) S-ECG (ram) 
C MS C MS 
Inffatmn I 29~:4 14÷3" 23±4 g±2"  
Innaf~n 2 18~3 15±3 15~3 11 ±2 
Inflation 3 16~3 14+-.3 12"-3 11 ~2 
Dunng the figst inflation, the ST-segment shift in both the IC-ECG and 
S-ECG was significantty attenuated in the MS group compared with controls 
(-51% and -60%). In contrel~, the ST shift was tess dunng the second 
and third inflation than dunng the first, indicating ischemic preconditioning. 
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In contrast, in trio MS group them was no additional decrease in ST shill 
during the second and third Inflation compared with the first. The reduction 
in ST shift altor,~od by MS during the first Inltetlon (--51% on IC-ECG vs first 
inflation in C) wets equivalent to that afforded by ischemlc preconditioning in 
controls (-~44% during the third vs first Inllallon), In conclusion, protroatment 
with MS mimics Iscbomle. preconditioning during PTCA, To our knowlodgo, 
these result9 provide the first evidence that morphine preeondltione humnn 
myoc~rdlum egemst I~chemia In viva end suggest that oplold recapture may 
play I1 r01e In the signaling pathways responsible for Ischemle precondition. 
Ing In rc~n, Bec¢t(mo of It~ efficacy and anlety, morphine could be used 
prophylactically to 11ttonuato i~chem111 In high risk PTCA, 
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~ Brief Antecedent "preconditioning" lachem/n 
A¢celttretee Coronary Thrombolyele In the ~nnlne 
Modal 
K, Przykl(~nl~, Ho,lrP In~ttflffe, Good S,Imwlrfffl~ Ho,qptf~f ,~ use, Los Angeles 
CA, USA 
B~lckgrol~nd; It Is w(dl-ost~bllsl~ed that brlsl episodes of antoctedont iachomia 
"pmenndltton" (PC) the heart ~nd rodll~11 infarct Sl~e Caused by stlbs0, 
quont ~ut~t~ined coronary occlusion, In {lddllion, recent shldlne from o=Jr 
labor~tory rove~led that bdnl antecedent PC Ischemia al~o 11ffonuate8 sub. 
~equont plrffelet aug'aeolian in damaged nnd 8tenotic coronary arteries by an 
adonoslno,medlated mechnnlsm, Our cgrmnt nlm wns to detelmlna whether 
the 11nltpl~tolot p~operties of PC Ischemie result iu morn rapid mpe~dugion rind 
better tnnlnl(~nnnco at '3t,b~equont vessel p~ton~,y in the t~otting el coronary 
thrombosls/lhrombol~sls, 
Mef/~,~: AneMhltttted oge undon~enl 10 mtn PC iscl~omla + 10 rain 
rollow (n ,. ?) or no intervention (n .  7) prior to Initiation of thrombotic 
eomn~iry aftory occlusion. At 1 I~ allot the onset of thmmbo.qL% el! dogs 
received 1,.3 mg/kg rt.PA, Primary study endpotnts included lifo timo required 
to achieve rollew', tht) duration of spontanoo(ls reoecluslon during the 2 
h 11liar initial lysts: and the total duration of thrombotic ocQlugmn (all with 
nonperercotrlc dlstrlbt, tlons and ff~uS reported as the median [2.5th', 7.51h] 
percentiles), Ae socondnry ondpolntn, collateral blood flow was moesured 
during thrombotic occlusion bv inlcctton 0l mdtolnbolod mtcmsphor08, and 
infarct si~e delineated oy toh(t,:olitml Bt(tinieg altd expressed a~ ~ % at Ulo 
myocardlum at risk. 
Results'. 
Control Procondlhonod 
Time to lyt~i~, (fnin) 47 113: 50] 1117; 14)" 
"rime ~pont mocchldOd (rain) 20 [21 521 (.~ re: 101 
T0t,'lt brae occluded thl 1 9 [1 ~,: 261 1 3 i1 1. I 41" 
The time roqu,od to achieve initial lysis was signilicanlly shortened, and 
mlbsequont vessel potency tended to be bettor maintained, in dogs that 
received ~ntocodent PC ischemia va controls ("p . 0.05). This was, not 
St.lrprlsingiy, accompanied by a signifiennt reduction in infarct size (11% v~ 
32% of the rlsk region; p • 0.0.5), despite comparable collateral pedusion, in 
the PC group. 
Conclusions: Briol preconditioning ischomia - in addition to its well-dec. 
umonted eardioprotectivo propedies - markedly shortens the time required 
for rt-PA-lndueod thmmbolysis in this canine model. 
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~ ln Viva Suppression of Myocardial Apoptotic Cell 
Death by Insulin-like Growth Factor IGF I and II 
M, Schoinowitz 1 . G. Sangiorgi 2, L.G SpagnolP, A. Or;d.dP, A. Kotlyar ~ ,
D, Hasdai ~. ~ The Neufeld Cardiac Research Institute, TeI-Aviv, Israel: 
~'Mayo Clinic, Rochesfer, USA: 3University of Rome Tar Vergata, Rome, Italy 
Background: Apoptosis (Ape) is a form of programmed cell death occurring 
in physiological and patophysiological slates including myocardial infarction 
(MI), Insulin-like growth factors (IGF) t and II have been shown to suppress 
Ape in vitro, but their in viva effects are unknown. The purpose of this study 
; i  
100  
Oo 
Norm l? Border  In f l rc t  
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was to examine the effects ot tntmcomnary IGF-I end II administration on 
myocardial Ape in acute MI, 
Motltods: Coronary mlcmembollzation was porlormed using 100. affigol 
beads in pigs randomly .assigned to 0,5 I~g IGF.I, IGF.II, or bovine albumin, 
incorporated within the beads and gradually released. Altar sacrifice at 4 
weoks, myocardial samples from tho Infarct (I), border (B), end normal zones 
iN) were asseeeod for Ape by TUNEL end Ilgatton.modlatod PeR, 
Results: TUNEL.posltlve celia wore obsontod particularly In 1 11nd B 11nd 
worn reduced In the treated antm1110~, Using PCR, IGF.I and II were also found 
to reduo0 the DNA ladderlng signal in I, with a eimllllr treed in I~ (~ee figure), 
Conchlsion~: Both IGF-I and II suppressed Ape in thi~ porcine, mod~l o! 
acute myocardial infarction, supporting ~ role for IGF.I 11nd .ll in regulating 
myocardial Apo in viva, 
tt:45 
~ U e a  of a Novel AntI-Apoptotlc Agent (LXR017) 
Reduces Infemt Sire Following 
la©hemle,Reperfuslon i  the Canine Myoeardlum 
M,,I, Silver, S,P, Chetcutl, DB~ Mukheqeo, J L  Matycky, D,L Tomei ! , 
S, Um~tnsky t , FA. Nicolini, The C/eve/and Clinic Fo~lr~tatlon, Clevel~Tr~, 
OH, USA; t l, J~R BtoteCflne/egy tim, Rchmond, CA, USA 
We h~ve previously shown that ~ phospholipld agent (LXRO17) spc'cific11!ty 
prevents apeptotio cell death induced by semmtglucoso depnvation, a Imlr- 
alia! to in-viva ischomia mpodusion iniury, in rat neonate! catdiomyocytes 
~inco apoptosis pl~ys a major rote in myocardial cell death following ischemia 
mpodusion, we sought to lest the efficacy of LXR017 in an in.viva model 
et ischomla mpodusion, Twenty open-chested dog~ um:lorwent emporan/ 
LAD occlusion (90 min) followed by rcpeduston (3 hrs). AI! dogs had con- 
tinuous monitoring el ECG, loll ventricual pressure, and alP/dr. Fifteen rain 
prior ropodusion, dogs wore randomly administered either an intracoronary 
infusion of placebo (n = 6), SOD.Catalnso (5 mg/kg; n = 5) a positive control 
group, or LXR0t? (250 .g; n = 9) for a total of 75 rain. Endpoints included 
infarct stt.o measured by TI'C staining (% el area at ask), regional shodenin9 
traction (SF) via sonomicmmotor crystals, regional myocardial blood llow 
via radioactive micresphems, and myelopemxidase (MPO) aetivdy. Baseline 
homodynamics as well aa regional myocardial blood flow were similar among 
groups and did not differ dunng the course el the study. Infarct size, MPO 
and SF findings at 3 hrs el repeduslon indicate that LXR0t7 prelects the 
tschom¢-mpertused cameo myocardium, and may provide a valuable new 
adjunct to repeduston therapy for acute myocardial infarction. 
Infarct Size (%) MPO IU/rnm'g) SF ~%) 
Placebo 22 ~ 2 0198 ~ 009 332 : 308 
SOD-Cat~Iso 11 ~ 6" 0096 t OO1" 28~ : 285" 
LXR017 10 4' 0094 ~ 003" 312 ~ 259" 
D¢~ta ,1[O Wesor~tod inme;.u~ ~ SD "P 0 04 '~s Pl~ct.!bo by ANOVA 
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]811-1) The Frequency of Familial Disease in a Consecutive 
Series o~ 51 Patients With Idiopathic Dilated 
Cardiornyopathy 
A. Gavazzi, M. Ponzetta, C. Campana, M. Giralch, C. Inserra, A. Raisaro. 
M.L. Laudisa, E. Colombi, B. Del Belle t , E. Arbustini ~ . Div~sione d~ 
Cardiotogia. Italy: w Istituto dl Anatomia Patotogica dell'Universita, IRCCS 
Policlinico S. Matteo, Pavia, Italy 
Background: Familial disease may account for a significant proportion of pa- 
tients with dilated cardiomyopathy (DCM) and coutd be more frequent han is 
often recognised. Most previous repeals are of anedoctal or retrospective na- 
ture and only a few prospective studies have been published, Consequently, 
the real fr, queney of fan,trial disease in DCM remains to be established. 
Methods: Our aim was to assess the frequency and mode of inheritance 
of lamilial disease by prospectively screening relatives from a series of 51 
consecutively diagnosed patients with DCM, The diagnosis of DCM was con- 
firmed invasively in every patient, All patients had a 2-3 generation pedigree 
constructed. Familial disease was diagnosed when at least one relative was 
affected by DCM. Screening consisted of history, clinica~ examination with 
blood pressure measurement, 12 lead ECG, two dimensional Doppler echo- 
cardiography, signal averaged ECG (SAECG) and blood sample (serum CK). 
